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Abstract
Phage display antibody libraries have proven an invaluable resource for the isolation of diagnostic and potentially thera-
peutic antibodies, the latter usually being antibody fragments converted into IgG formats. Recent advances in the produc-
tion of highly diverse and functional antibody libraries are considered here, including for Fabs, scFvs and nanobodies. 
These advances include codon optimisation during generation of CDR diversity, improved display levels using novel signal 
sequences, molecular chaperones and isomerases and the use of highly stable scaffolds with relatively high expression levels. 
In addition, novel strategies for the batch reformatting of scFv and Fab phagemid libraries, derived from phage panning, 
into IgG formats are described. These strategies allow the screening of antibodies in the end-use format, facilitating more 
efficient selection of potential therapeutics.
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Introduction
Phage display libraries based on M13 filamentous bacte-
riophage can present a vast diversity of antibody fragments 
on the pIII minor coat protein, utilising either a phagemid 
or phage vector system to encode the antibody-coat protein 
fusion (the different display systems including mutated 
helper phage are reviewed elsewhere, [1–3]). The presence 
of the antibody on the surface of the phage particle is accom-
panied by the gene for the antibody being packaged within 
the phage. In this way the phenotype (antibody binding) and 
the genotype (antibody gene) are linked [2]. Within stand-
ard panning methods, the highly diverse antibody library is 
introduced to an immobilised antigen and unbound phage 
washed away, bound phage are then eluted, usually by a shift 
in pH and the resulting sub-library propagated in Escheri-
chia coli to amplify each phage clone. Such panning cycles 
are usually carried out 3–5 times to enrich for phage-anti-
bodies that bind to the target antigen and hundreds of single 
phage clones are then isolated, propagated and tested in ELI-
SAs [2]. More recently, screening has used next generation 
sequencing platforms to sequence thousands to millions of 
antibody genes contained within the selected sub-libraries 
of phage after panning. Sequencing usually targets the whole 
VH or the CDRH3 domain. These methods allow a thorough 
investigation of the enrichment of phage clones, even when 
they are minor components of the sub-libraries [4–6]. Phage 
display libraries can enable the identification of a variety 
of antibodies with desirable binding properties including 
antibodies that bind to toxic or non-immunogenic antigens.
Naturally occurring or designed antibody domains have 
been developed that are suited for phage display but still 
retain the binding properties of a full-length IgG (Fig. 1). 
These domains include antigen binding fragments (Fab), 
single chain Fv (scFv) and single domain antibodies 
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(nanobodies). The latter include camelid  VHH and shark 
 VNAR (New Antigen Receptor).
Phage antibody libraries are classed as naïve, semi-
synthetic, synthetic or immune libraries [2]. The latter are 
produced by cloning the antibody genes from immunised 
animals (e.g. [7–9]) or diseased or vaccinated humans [10, 
11] and are directed towards a single or limited number of 
antigens. Naïve phage display libraries are produced from 
the natural antibody repertoire of donors. Alternatively, 
phage display libraries can be produced using a relatively 
small diversity of natural antibody sequences whose diver-
sity is increased through mutating one or more complemen-
tarity determining regions (CDRs) (semi-synthetic librar-
ies). Libraries can also be based on a single or very low 
number of “scaffold” sequences with introduced diversity 
in the CDRs (synthetic libraries). Immune libraries require 
Fig. 1  Representations of the 
different structures of antibod-
ies and antibody fragments for 
phage display. The multi-
domain structure of conven-
tional IgG and heavy chain 
antibody (camelid and shark) 
(a). Antibody fragments can 
be displayed on phage as Fabs, 
scFvs or nanobodies  (VHHs or 
 VNAR, derived from camelid 
or shark, respectively). The 
synthetic scFab-Fc dimer is also 
shown (b). V variable domain, 
C constant domain, H heavy 
chain, L light chain
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immunisation and library cloning for each antigen but small 
repertoire libraries (~ 106) usually facilitate the isolation of 
high affinity binders (e.g. [7–9]). On the other hand, naïve 
or synthetic/semi-synthetic libraries (collectively known 
as single-pot libraries) can be used against any antigen but 
are required to have very high diversity (typically > 1010) to 
allow the isolation of high affinity binders (e.g. [12–16]).
In terms of antibody formats, Fabs consist of the VH-CH1 
and VL-CL chains, one of which is fused to the pIII protein 
[17]. In phage display systems these two chains are usu-
ally expressed separately and assemble into the Fab format 
within the periplasm of the bacteria via a disulphide bond 
linkage. ScFvs consist of just the VH and VL chains joined 
together by a peptide linker with one chain fused to the pIII 
protein [12]. This single chain is expressed and targeted to 
the periplasm where the scFv folds into its active conforma-
tion. Nanobodies are an alternative antibody fragment and 
at just 12–15 kDa are smaller than Fabs or scFvs. They are 
derived from natural heavy chain antibodies found in came-
lids and sharks that lack a light chain (Fig. 1a). Nanobodies 
consist of the equivalent of a conventional IgG VH domain 
and again can be fused to the pIII phage protein for display 
[18, 19].
Examples of all of these antibody types with high speci-
ficity and affinities in the low nM to pM range have been 
directly selected by phage display (Table 1). A consideration 
when developing a single-pot antibody phage display system 
is that a high diversity will be more likely to deliver the best 
binders and the higher the level of display the more effec-
tive the selection of these binders will be. High specificity 
and affinities enable them to be effective in their applica-
tions such as for drug delivery, therapeutics, in vivo imag-
ing or diagnostic assays. Recombinant antibody fragments 
are relatively small and lack an Fc domain. Considering 
in vivo applications, these properties may have advantages 
where high tumour/tissue penetration and a short half-life 
are advantageous, such as for in vivo imaging [20, 21]. In 
contrast, most protein therapeutics are based on human/
humanised antibody fragments that are converted into larger 
antibody structures such as IgG. A strategy designed to min-
imise immunogenicity, elicit effector functions and extend 
serum half-life [22]. The use of recombinant antibodies 
as therapeutics is of increasing importance. In a review in 
2016, Frenzel et al. reported that there were 64 phage display 
derived antibodies or antibody conjugates that had under-
gone some stage of clinical trials and the vast majority of 
these antibody fragments had been converted to IgG or IgG-
conjugate formats [23]. A more recent update in 2019 stated 
that over 80 phage display derived antibodies had entered 
clinical studies and more than 10 had marketing approval 
[24].
This review will consider recent advances in the cloning 
and functional display of antibody libraries, as well as their 
batch reformatting into IgG-like molecules.
Antigen Binding Fragment (Fab)
Fabs were one of the first type of recombinant antibody that 
was produced as a diverse repertoire displayed on the sur-
face of bacteriophage, first being described in 1991 [17]. 
As mentioned above, antibodies will usually be required to 
have high specificity and affinity and therapeutic applica-
tions may require the antibody to be converted into an IgG 
format. Ideally, this reformatting would be done before the 
screening of antibodies resulting from phage display panning 
as the binding properties of the monovalent Fab will be dif-
ferent from the divalent IgG [21, 25, 26]. In addition, high 
expression levels and high stability of Fab and IgG are vital 
to produce useful reagents [25].
There have been several recent reports on the production 
of Fab phage display libraries with either simplified cloning 
strategies or improved/distinct diversity. Typically, the light 
chain VL-CL gene will be expressed separately from the 
VH-CH1-pIII fusion gene. Both proteins are targeted to the 
periplasm where they interact to form a Fab-pIII fusion that 
is then packaged into assembling phage.
Type II restriction enzymes have been used in a so-called 
‘seamless’ cloning strategy for Fabs. After screening human, 
rabbit and mouse antibody gene repertoires, enzymes were 
selected that either did not cut or cut very infrequently in 
antibody gene sequences. Appropriate phagemid vectors 
were then produced including these restriction enzyme 
cleavage sites for the cloning of human (using BsmBI and 
Table 1  Comparing high 
affinity ligand types that can be 
used in phage display
*Before affinity maturation
Ligand type ~Size (kDa) Typical affinity range 
of selected clones*
Reference examples
Antigen binding fragment (Fab) 55 nM-pM [29, 100]
Single chain variable fragment (scFv) 25 nM-pM [12, 35]
VHH 15 nM-pM [101, 102]
Shark  VNAR 12 nM [19, 90]
Human VH or VL single domain antibodies 15 μM-nM [64–66]
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SapI, vector pUP-22Hb), rabbit (SapI only, vector pUP-
22Rc) and mouse (SapI, vector pUP-22Mc) Fabs, and librar-
ies of diversities ~ 109 produced [27]. These libraries only 
use kappa light chains and this strategy clones amplicons 
of VH and VL into the vector in a single step. Whilst this 
was applied to produce immune libraries only (the human 
library was a mouse/human chimeric library), the repertoire 
achieved for the libraries demonstrates the strategy is appli-
cable to produce more diverse single-pot Fab libraries.
It has been reported that rabbit B cell repertoires may be 
very different to those of human or mice due to the unique 
ontogeny of rabbit B cells and extensive somatic gene con-
version [28]. Peng et al. [29], recently produced a naïve rab-
bit/human chimeric Fab library of ~ 1010 diversity made up 
of rabbit VH/VL regions and human CH1 and CL domains. 
The strategy used multiple step wise PCR amplifications 
of the VH and VL genes for use as part of the templates 
in a 3-fragment overlap extension PCR to amplify VL-CL-
VH for Kappa and Lambda light chains, and the subsequent 
cloning of the products into a CH1 containing vector. The 
study selected a range of antibodies with high specificity and 
affinities in the low nM range.
When synthetic diversity is added into libraries it is usu-
ally targeted at the CDRH3 and CDRL3 domains as they 
are reported to have the greatest influence on specificity and 
affinity [30]. One recently produced library used the scaffold 
Fab Hu4D5-8 that has high thermal stability. Limited diver-
sity was introduced into the CDR1 and CDR2 of both heavy 
and light chains with sequences matching the most canonical 
CDR conformations in the scaffold sequence. High random 
sequence diversity was then introduced into CDR3s (7–25 
residues) to produce a library repertoire of 7 ×  109. The 
strategy also used a previously described bivalent display of 
Fabs which are displayed in a Fab-GCN4 leucine zipper-pIII 
display format and includes intermolecular disulphide bond 
sites [31]. Fabs were isolated with ~ 2 nM affinities.
There are several commercially available Fab libraries, 
for example the Ylanthia library from MorphoSys [30]. 
This library has very high diversity and is based on 36 fixed 
heavy/light chain pairs selected from 400 combinations that 
were characterised for desirable biophysical properties. 
These were relatively high expression in bacteria and mam-
malian cells as Fabs or IgG, respectively, high display lev-
els on phage, high thermal stability and low aggregation in 
both Fab and IgG formats. CDRH1 and CDRH2 had limited 
diversity introduced to remove sites for post-translational 
modifications (PTM). High diversity was then introduced 
into CDRH3 and CDRL3, again avoiding PTM sites, to pro-
duce a library of  1011 clones. One clone selected by panning 
had an affinity of 700 pM. A range of clones gave yields 
ranging from 1.5–13 mg/L and when converted into IgG 
and transiently expressed in HKB11 cells, 20–80 mg/L IgG 
was produced.
Stability of the Fab and concomitant IgG is an impor-
tant factor in library design and can be addressed as above 
by selecting scaffold Fab structures with high thermosta-
bility. An alternative approach isolated thermostable scaf-
folds by transiently heating a Fab phage library before 
selection of functional Fabs with an anti-light chain anti-
body [32]. Five unique Fabs were identified and each had 
increased stability. Combinations of the Fabs’ mutations 
resulted in an optimal triple mutant with high stability that 
also translated into a similarly highly stable IgG. It was 
speculated that the CDRH1 region mediated this increase 
in stability.
Insufficient solubility can often lead to candidate anti-
bodies not being fully developed for diagnostic or thera-
peutic applications. In silico programmes that can predict 
antibody solubility have been applied to Fabs that have been 
converted into IgGs. The predictions from these in silico 
programmes have been compared to a range of in vitro tests 
for protein aggregation, stability and solubility [33]. Sev-
enteen antibody variants with a wide range of predicted 
solubilities were characterised and the in silico prediction 
tools displayed significant correlation with the in vitro test. 
The authors concluded that the CamSol programme could 
be used to efficiently identify lead antibodies to take forward 
for development. This provides a rapid and cost-effective 
method for improved selection of lead antibodies. Such in 
silico stability prediction tools may also have application 
to the design of a high solubility Fab scaffold for synthetic 
library production. Whilst the selection of such a scaffold 
may help facilitate the selection of high solubility reagents, 
this may be limited by the mutated CDR regions making 
significant contributions to the solubility of the Fabs. Post-
panning solubility testing will therefore still be required.
Fabs are often reported as having relatively low phage 
display levels compared to scFvs, which may be attributed to 
their relatively complex disulphide bond formation [26, 34]. 
Several recent studies have looked to improve Fab display 
levels. Huovinen et al. [35] compared the panning enrich-
ment of the same Fab repertoire on pIII (rescued with wild 
type helper phage or hyperphage), truncated pIII and pIX (a 
minor coat with ~ 5 copies per phage particle, the same as for 
pIII). They also compared scFv displayed on truncated pIII. 
Fab displayed on pIX had the lowest selection efficiency, the 
highest diversity of clones was obtained with Fab or scFvs 
displayed on truncated pIII. Increasing the display valency 
with hyperphage improved the selected clone diversity. It 
was shown that a single propagation of phage resulted in 
large reductions in diversity of antibodies for the Fab-pIII 
and scFv-truncated pIII libraries, where frameshift muta-
tions seemed to be selected for. The study indicated that 
the optimal display of Fabs was on truncated pIII and this 
may be further improved by increasing Fab valency using 
hyperphage.
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The use of co-expression of molecular chaperones or 
isomerases to improve Fab folding/stability and export into 
the periplasm has also recently been reported. For example, 
co-plasmid expression of DsbA, DsbC, FkpA and SurA has 
been used. The expression of the peptidyl prolyl cis–trans 
isomerases (PPIases) FkpA and SurA directed to the peri-
plasm may improve folding, and DsbA and DsbC help opti-
mise disulphide bond formation [34]. The selection of Fabs 
during panning was greatly improved with much higher lev-
els of Fab detected on phage through each round of panning 
compared to when the co-plasmid was not present. A study 
by Levy et al. [36] also used co-expression of the PPIase 
FkpA, but it was retained in the cytoplasm or directed to 
the periplasm. Functional Fab levels were improved to a 
greater extent when the FkpA was expressed in the cyto-
plasm. During panning, the system improved the diversity of 
antigen specific Fabs from 10–16% to 43–48%. The authors 
speculate that FkpA isomerises proline residues in kappa 
light chains and when subsequently exported to the peri-
plasm this improved folding and Fab assembly. The strategy 
improved periplasmic soluble Fab levels from 0.4–2.5 mg/L 
to 3.5–14.2 mg/L.
A different approach displayed single chain Fabs (scFab) 
where the C-terminal of the light chain was linked via an 
extended 60 amino acid linker to the N-terminus of the 
heavy chain [25]. This extended linker allowed retention of 
the interchain disulphide bond (shorter linkers necessitated 
the removal of this bond) and effective scFab display. The 
authors speculated that this approach of tethering of the Fab 
chains may increase the folding rate. The study also looked 
at optimising the secretion of the Fabs by routing through 
the signal recognition particle (SRP) pathway for co-trans-
lational secretion and comparing this to the more usually 
employed secretion of the unfolded post translation scFab 
proteins. The former used the signal sequence from DsbA 
and the latter the pelB signal sequence. The hypothesis was 
that co-translational secretion would prevent any scFab fold-
ing in the cytoplasm that may reduce efficient folding/secre-
tion. In addition, the study also selected optimised mutants 
of the signal peptides and found 3 mutants of pelB and 2 
of the DsbA signal sequence with improved display levels. 
Overall, using an optimised DsbA signal sequence resulted 
in a threefold improvement in display to 0.5 scFabs/phage 
particle. In terms of scFab expression levels, soluble scFab 
was improved from 1–3 mg/L to 3–4 mg/L when switching 
to the co-translational secretion system.
It is often desired to convert Fabs into full-length IgGs 
as the final antibody reagent. This is often not a straight 
forward procedure and usually takes 2 steps, each of which 
sequentially clones the VH and VL (or whole light chain) 
domains into an expression vector. Either using a single 
expression vector (Fig. 2a) or more usually by cloning the 
light and heavy chain domains into distinct vectors [37]. As 
these conventional reformatting strategies clone the heavy 
and light chain variable regions independently they are 
unsuitable for batch cloning, where heavy and light chains 
would need to retain their pairing. Screening recombinant 
antibodies from phage display in an IgG format is therefore 
labour intensive and presents a bottleneck in discovering 
functional IgGs [37]. Jostock et al. [21] reported vectors that 
could express Fabs as human IgG1 or IgG4 or mouse IgG2a 
antibodies. These also allowed Fab regions to be switched 
between vectors. The cloning strategy retained the pairing 
of light and heavy chain regions and so could be applied 
to the batch cloning of Fabs from phagemid into the IgG 
expression vectors. The method readily recovered ~ 90% of 
the Fabs, allowing screening to be done with divalent IgGs 
produced in mammalian cell culture (see Fig. 2b for clon-
ing details). Transient expression in HEK293T cells pro-
duced 5–18 mg/L IgG. An alternative approach has been 
described that uses a vector (pDV) that is compatible with 
both bacterial expression of Fab and mammalian cell expres-
sion of full-length heavy chain without sub-cloning [26] (see 
Fig. 2c for cloning details). Fab diversity was only within 
the heavy chain in the pDV library. The system was based 
on a signal sequence from murine binding immunoglobulin 
protein (mBIP) that can support secretion of heavy chain 
sequences in both cell types. A stop codon after the pIII 
protein prevents the expression of the Fc region within bac-
teria. The pIII gene and stop codon were sited within an 
intron and were removed by RNA splicing in mammalian 
cells allowing expression of full-length heavy chain. Within 
the mammalian cells an invariable light chain was expressed 
from a separate vector to allow IgG formation. A library of 
 109 diversity was produced and panning allowed selection 
of specific Fabs. Cognate IgGs were transiently expressed 
and several had affinities in the low nM range. The levels 
of IgG produced were 2–6 mg/L which is lower than with 
other expression vector systems but was sufficient for screen-
ing antibodies. Alternatively, the scFab system described by 
Koerber et al. [25] allowed batch cloning in a single step to 
an scFab-Fc format (scIgG; see Fig. 2d for details), made up 
of IL2 signal peptide-scFab-rabbit Fc. Transient expression 
in HEK293T cells yielded 5 mg/L scIgG.
Single Chain Variable Fragments (scFv)
ScFvs offer high sensitivity, specificity and ease of expres-
sion in different systems. Unlike Fabs, scFvs are expressed 
from a single gene and the variable regions are tethered by 
a flexible linker, improving both expression and refolding/
assembly [38]. However, they can display lower affinity than 
the corresponding Fab and can have lower long-term stabil-
ity [39]. The production and utility of scFv-phage librar-
ies and the screening and application of the binders have 
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the same issues as outlined for Fabs. High diversity single-
pot libraries are required to produce high affinity reagents 
against any target [40] and numerous libraries containing 
greater than 10 billion clones have been reported [41–43]. 
Consistent, high stability and high expression levels in both 
bacteria and mammalian systems for all library clones would 
Fig. 2  A summary of key elements within different strategies to pro-
duce full-length IgG or Fc-fusion constructs from Fab phage display 
vectors. Conventional cloning of Fab usually includes the amplifica-
tion of the VH and VL domains and cloning into appropriate sites 
within an ‘IgG cassette’ that contains the CL and CH1, CH2 and 
CH3 domains within a mammalian expression vector (a). For Fabs, 
an analogous 2 step cloning method can be used to clone the entire 
light chain along with the VH domain (A, dashed primer would be 
used). The phagemid (left hand side) will contain E. coli promoter (p) 
and leader (l) sequences for the expression of the Fab. The antibody 
fragment gene is expressed as a fusion with a downstream gIII phage 
coat protein gene. Once the VL (or light chain) and VH domains are 
cloned into the IgG expression plasmid, the light and heavy chains 
are expressed separately with their own eukaryotic promoter (p) and 
leader (l) sequences and poly(A) tail (A) [mammalian regulatory ele-
ments are  indicated in grey font]. Fabs have also been cloned from 
a phagemid vector in two steps into a mammalian expression vector 
to retain the pairing of the light chain and VH-CH1 domains, allow-
ing batch cloning of polyclonal phagemid [21] (b). In the first step 
the Fab is amplified and cloned into the vector and then in a second 
step the mammalian regulatory elements are introduced between 
the light chain and heavy chain genes. With a Fab library that only 
contain heavy chain diversity, this can be expressed within Fab or 
full-length IgG formats from the same vector (c). The pDV system 
[24] expresses the Fab or IgG when in E. coli or mammalian cells, 
respectively, without any requirement for sub-cloning steps. The 
construct uses a bacterial  p and l for the light chain and has a bac-
terial transcription terminator (t) after the light chain. The sequence 
upstream of the VH-CH1 genes contains bacterial and eukaryotic 
promoters along with a leader sequence that functions in either host 
cell (L). Downstream of the gIII gene is a stop codon (*) followed by 
a splice domain (S). A second S is present between the CH1 and gIII 
domains. In bacteria, Fab-gIII is expressed and in mammalian cells, 
intron splicing (dashed lines) removes the gIII region and the heavy 
chain is expressed and paired with an invariant light chain derived 
from a different vector. Alternatively, single chain Fabs expressed as 
fusions with pIII can be sub-cloned in a single step into a mammalian 
expression vector containing the Fc domain to make scFab-Fc [25] 
(d)
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be a valuable trait to allow the isolation and development of 
the best binders. As with Fabs, scFvs have relatively high 
tumour penetration compared to IgG and a rapid in vivo 
clearance, making them useful tools for in vivo imaging 
[44–46]. However, many applications require divalency 
and Fc region availability, and so the batch reformatting of 
scFvs into IgGs or scFv-Fc formats for screening would be 
of value [40].
For scFvs it has been reported that the contribution of the 
distinct domains to the antigen binding site is in the order 
CDRH3 > CDRH2  > CDRL3 > CDRH 1 > CDR L1 > CD R L2 
> F ramework regions [40] . N aïv e lib rar ies ar e traditional 
ly  pro du ced by se quential amplification and cloning of the 
VL and VH regions into a phagemid vector separated by a 
(Gly4-Ser)3 linker [47]. They usually then contain c-myc 
and polyHis tags between the C-terminus of the scFv and 
the N-terminus of the pIII coat protein. Kugler et al. [43] 
demonstrated that the order of the tags can influence soluble 
scFv expression levels in bacteria. They reported yields in 
the low mg/L range which is similar to those produced after 
sub-cloning of scFvs into a pET expression vector [48]. As 
CDRH3 has the highest natural diversity and contributes the 
most to the antigen binding site [40], synthetic and semi-
synthetic libraries invariably target this region for mutagen-
esis, sometimes along with other CDRs. For example, the 
Tomlinson I and J library mutated CDR2 and CDR3 regions 
of both VL and VH [13], the HuCal scFv library mutated 
CDR3s and the HuCal GOLD library introduced diversity 
into all CDRs [14–16].
ScFv libraries are usually produced using multiple PCR 
reactions to amplify diversity and introduce the linker region 
and then assembly of scFv chains via overlap extension 
PCR. However, this can result in mis-annealing, particu-
larly in the linker repeat region, and produce non-functional 
fragments. Nishi et al. [49] used this method to produce 
a synthetic library with randomised CDR3s which had a 
diversity of ~ 108 but 8 out of the 13 clones sequenced had 
errors. Libraries of diversity ~ 1011 made by an analogous 
method contained 66–85% clones with ORFs and 58–85% 
expressed soluble protein [40]. An alternative method intro-
duced diversity through PCR and cloning of the VH and 
VL libraries separately into a pUC vector along with partial 
linker sequences containing a unique restriction site. This is 
then followed by sub-cloning of the libraries into a phagemid 
vector to form scFv cassettes without further PCR amplifica-
tion. This strategy produced much higher levels of functional 
scFvs, with no errors found in 83 sequenced clones [49].
Weber et al. [50] used single VH and single VL kappa and 
VL lambda genes as the scaffolds for a synthetic scFv library 
where they introduced mutations into CDR3s with partially 
degenerate primers. They also chose asparagine at residue 52 
of VH as this mutation is often present due to somatic hyper-
mutation and during affinity maturation. The VH selected as 
scaffold had high thermal stability and also bound protein A 
when part of an scFv. The resulting PHILODiamond library 
had ~ 1010 diversity with 90% of clones having a functional 
scFv. They speculated that as only the CDR3s were mutated, 
affinity maturation of clones could be carried out by intro-
ducing diversity into the CDR1 and 2 loops.
Codon usage for mutagenesis in synthetic or semi-syn-
thetic libraries is often NNN or NNK but can also be more 
tailored such as the use of NWG, NWC and NSG codons 
(where N = A/T/G/C, K = G/T, W = A/T, S = G/C) to avoid 
the introduction of cysteines and stop codons (other than 
amber) into CDRs [51]. Säll et al. [52] introduced an even 
more specific mutagenesis strategy. They used trimer phos-
phoramidite codons to predetermine the diversity introduced 
into and adjacent to CDRHs and CDRL3. The strategy intro-
duced up to 13 amino acids into any one position and was 
based on the diversity of commonly found residues in natu-
ral repertoires, with particular bias for tyrosine, glycine and 
serine residues. The strategy also varied the length of the 
CDR3s. The library used single human scaffold VH and VLs 
(kappa and lambda) with codon optimisation for expression 
in bacteria and mammalian cells. Two libraries were pro-
duced, HelL-11 and then HelL-13 with diversities of ~ 1010. 
The former library had stop codons in both CDR3s of the 
scaffold scFv and the resulting library displayed just 47% 
functional scFvs, it was also found that tryptophan was over-
represented within the diversity regions relative to the con-
comitant codon usage in the oligonucleotide synthesis. The 
HelL-13 library was adjusted to remove tryptophan bias and 
also used a scaffold scFv with a stop codon only in CDRH3. 
This resulted in 60% of clones having a functional scFv and 
it was found that functional scFvs selected against various 
targets paired the scaffold CDRL3 with numerous CDRH3s.
A semi-synthetic human scFv library (ALTHEA Gold) 
has been produced that selected for highly diverse thermo-
stable scaffolds before introducing a natural CDRH3 diver-
sity [53]. Firstly, two kappa VL domains and a single VH 
domain had diversity introduced using trinucleotide phos-
phoramidites. These mutations coded for amino acids found 
in natural repertoires at 10 positions within the VH (within 
CDRH1 and CDRH3) and at 10 or 12 positions within the 
two VLs (within all 3 CDRs). Further diversity was then 
added by cloning 90 neutral CDRH3 containing fragments, 
resulting in a library of ~ 1 × 109 diversity. The selection for 
high-stability scFv-phage clones was then carried out by 
heating the library for 10 min at 70 °C and purifying sta-
ble, native scFvs on protein A (that binds the particular VH 
used). This thermostable library of scaffolds was then fur-
ther diversified by the introduction of natural CDRH3 frag-
ments from 200 donors. The resulting library had a diversity 
of ~ 1010. Binders were selected from the library and once 
converted to IgG they displayed affinities in the very low 
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nM to pM range. These IgGs were produced at 50–90 mg/L 
in HEK293 cells.
An alternative approach to scFv library construction has 
been recently described by Zhao et al. that used the modular 
cloning of different CDR regions [54]. Antibody sequence 
databases were mined for heavy and light chain CDR2 and 
CDR3 sequences contained within a particular scFv frame-
work. The rationale was that such modular domains are 
known to be functional and the approach would avoid non-
functional clones present in synthetic/semi-synthetic librar-
ies. Non-functional clones could arise due to incompatibility 
between CDR mutations and the framework scaffold(s) and/
or incompatibility between amino acid combinations within 
highly mutated CDRs. Based on 2000 scFv sequences, shuf-
fling of the 4 CDR regions produced a library of ~ 1010 diver-
sity. This so-called predefined CDR sequences (PDC) library 
was estimated to produce 20-fold more unique functional 
scFvs per target compared to libraries produced with degen-
erate oligonucleotide methods.
As with Fabs, in silico programmes that can predict anti-
body solubility can also be applied to phage-scFv panning 
outputs. The aim being to select high affinity binders that 
also have high solubility without the need for extensive 
in vitro testing. Sormanni et al. compared the CamSol pro-
gramme to in vitro solubility tests using nine IgGs derived 
from scFvs isolated by phage display [55]. Hotspots linked 
to aggregation were identified within the scFv domain and 
solubility could be accurately predicted. Such in silico sta-
bility prediction tools have now been validated with Fabs 
and scFv domains to improve lead antibody identification.
As with Fabs, the reformatting of scFvs into IgGs is 
important for various applications including the develop-
ment of therapeutic antibodies. Standard methods involve 
the sequential cloning of VL and VH genes into appropriate 
IgG expression cassette vector(s), analogous to that for Fabs 
(Fig. 2a). Alternative methods that allow the batch cloning 
of scFv sub-libraries after panning selection would be far 
less labour intensive than cloning individual clones. Such 
methods would also allow the screening of IgGs for function 
and therefore facilitate the selection of antibodies with the 
best properties for the end application. This latter trait has 
been termed ‘screening in product format’ (SiPF) by Xiao 
et al. [56]. As with Fab cloning, the challenge is maintaining 
the VL-VH pairing during the batch reformatting. Liu and 
co-workers retained VL-VH combinations when reformat-
ting an scFv sub-library into an IgG format by using overlap 
extension emulsion PCR [57]. The method produced 1 × 104 
IgGs from a panning sub-library and the diversity and rela-
tive abundance of clones correlated between the original 
scFv library and the IgG resultant library. Batonick et al. 
[58] developed a system to reformat scFv into IgG that takes 
advantage of both bacterial integrases and also intron splic-
ing in mammalian cells. Their system, termed pMINERVA, 
uses a phagemid ‘donor’ that contains mammalian and bac-
terial promoters and an scFv with a linker between the VH 
and VL genes that is also the substrate for phiC31 integrase. 
The construct also contains splice sites either side of the gIII 
gene. The gIII gene has an ochre stop at its 3′ end followed 
by a splice site and the CL domain (Fig. 3a). The vector con-
taining the scFv of interest is transduced into an E. coli strain 
that expresses the integrase and contains an ‘acceptor’ plas-
mid. This plasmid contains the CH domain as well as regula-
tory elements for mammalian expression (of the light chain). 
The plasmids undergo specific recombination resulting in 
an IgG expression vector where, in mammalian cells, the 
gIII region is removed by intron splicing resulting in expres-
sion of light chain and heavy chain (Fig. 3a). Efficacy was 
demonstrated for a single scFv and the method may allow 
batch reformatting of scFvs of the original library produced 
in the ‘donor’ phagemid. An alternative system also allow-
ing batch reformatting uses inverse PCR to amplify VH and 
VL within a whole phagemid, effectively producing linear 
phagemid and removing the linker sequence [59]. This also 
introduces complementary overhangs. The latter are also 
used in the separate amplification of a donor fragment con-
taining a hinge-CH region, translation stop and polyA sites 
and the control elements for light chain expression (promoter 
and leader sequence). InFusion [60] technology is then used 
to fuse this donor fragment into the phagemid. This IgG 
cassette is then PCR amplified and cloned into a mamma-
lian expression vector containing the promoter and signal 
sequence for the heavy chain, the CL domain (either kappa 
or lambda) and a polyA site (Fig. 3b). When using emulsion 
PCR to limit recombination between clones, the accuracy of 
this batch reformatting was 90% in terms of VH-VL pairing. 
The study suggested that reformatting retained the relative 
abundance of clones in an scFv pool and when reformatting 
25 scFvs, 84% were successfully obtained as IgGs (the miss-
ing clones were present just once in the scFv pool when 129 
clones were sequenced). Furthermore, when assessing the 
expression levels of the IgGs, in 293F cells, clones produced 
0.4–40 mg/L IgG. When using Expi293F cells, expression 
levels were between 1 and > 200 mg/L for the 1500 clones 
assessed. The system is compatible with any pre-existing 
scFv library and results in high fidelity batch reformatting 
and consistent, high-level IgG production.
An alternative to converting scFvs into IgGs is to pro-
duce scFv-Fc fusions by cloning the scFv into a mammalian 
expression vector containing the Fc domain in a single step. 
This format has been shown to produce 10–20 mg/L in 239T 
cells, which can be optimised to up to 600 mg/L [61]. Simi-
larly, Xiao et al. [56] developed a vector that allows both 
bacterial and mammalian expression of scFv-Fc fusions. The 
system, pSplice, is based on a vector that contains mam-
malian expression control elements followed by an intron 
coding for a bacterial promoter and signal peptide and then 
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the scFv-Fc gene. In mammalian cells, the intron is spliced 
out to produce a functional operon for scFv-Fc (Fig. 3c). 
This vector system is designed to allow the rapid screening 
of scFv-Fc using bacterial expression before the transfer of 
selected clones to mammalian cells. Both systems have the 
potential to batch clone scFv pools after panning to allow 
the screening of bivalent antibodies.
Another recent advance in scFv-phage display technology 
is the production of functional, renewable polyclonal scFv 
reagents. Polyclonal antibodies produced in vivo are not 
Fig. 3  A summary of key elements within different strategies to pro-
duce full-length IgG or Fc-fusion constructs from scFv-phage display 
vectors. A conventional 2-step cloning strategy for scFvs is analo-
gous to that for Fabs shown in Fig. 2a. Alternatively, the pMINERVA 
system [58] utilises both bacterial integrases and also intron splicing 
in mammalian cells (a). A phagemid ‘donor’ vector contains mam-
malian (grey font) and bacterial (black font) promoters and a leader 
sequence compatible with both cell types (symbols are the same as in 
Fig. 2), in addition the scFv has a linker that is also the substrate for 
phiC31 integrase (in). The construct also contains splice sites either 
side of the integrase substrate region and either side of gIII. The gIII 
has an ochre stop at its 5’ end followed by the CL domain. The con-
struct can be transferred to an E. coli strain that expresses the inte-
grase and where a second acceptor plasmid is present that contains 
the CH domain (CH1-CH2-CH3) and regulatory elements (p and l) 
for mammalian expression of the light chain. Integrase mediated 
recombination results in an IgG expression vector where, upon trans-
fer to mammalian cells, intron splicing (dashed lines) results in the 
removal of the gIII region and expression of light chain and heavy 
chain. Alternatively, InFusion technology, allowing the cloning of 
overlapping 15 bp sequences, has been used in a multi-step cloning 
strategy to produce IgG from scFv [59] (b). The phagemid was ampli-
fied by inverse PCR to produce a linear version of the whole vector. 
This step removed the scFv linker and added an overlapping sequence 
(indicated by …). This same overlapping sequence was added in a 
separate PCR reaction to a DNA fragment containing CH domains 
and mammalian promoter and leader sequences (amplified from a 
‘donor’ vector). InFusion cloning produced the heavy chain and VL 
region, the latter with mammalian regulatory elements, that are then 
amplified by PCR and subsequently cloned using InFusion into a 
mammalian expression vector containing the regulatory elements for 
the heavy chain as well as the CL domain. ScFv from phagemid can 
potentially be batch cloned into a vector (pSplice) that can express 
scFv-Fc in both bacterial and mammalian cells [56] (c). The scFv 
could be amplified by PCR and cloned into the pSplice vector that 
contains a mammalian promoter and leader sequence in addition to E. 
coli promoter and leader sequences, all upstream of the scFv-Fc cod-
ing region. The mammalian leader sequence is incomplete with the 3′ 
region contained after the prokaryotic p l sequences that are flanked 
by splice domains. The scFv-Fc is expressed from the cassette in E. 
coli and in mammalian cells the intron containing the bacterial regu-
lation elements is excised (dashed lines) and the mammalian leader 
sequence spliced together allowing expression of the scFv-Fc
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renewable and can often contain as little as 0.5–5% target-
specific antibodies [62]. The strategy to combine the use of 
phage and yeast display to screen for binders was described 
by Ferrara et al. [63]. Two rounds of phage selection against 
a target were followed by PCR amplification of the scFv sub-
library (representing ~ 105–106 clones) and batch cloning 
into a yeast surface display vector. Two rounds of fluores-
cence activated cell sorting resulted in ~ 63% of scFv clones 
binding the target and all scFvs had low background binding. 
This polyclonal scFv reagent was highly specific and could 
be regenerated after dilution of over a 100 million-fold with-
out loss of function or relative abundance of the clones. The 
affinities of the reagents were ~ 50–500 nM which reflected 
the concentration of antigen that was used in the panning. 
Such a strategy may have advantages over generating mono-
clonal ligands when targeting complex antigens presenting 
multiple epitopes.
Human Single Domain Antibodies
Whilst far less utilised than scFv or Fab phage display librar-
ies, several single domain human antibody libraries derived 
from either VH or VL regions have been described and char-
acterised [64, 65]. These are relatively easy to produce as 
synthetic or semi-synthetic libraries. However, the disadvan-
tages of these antibody formats are the unreliable isolation 
of target-specific clones by phage display, relatively low sta-
bility, low solubility and often relatively poor affinities [64, 
65]. Henry et al. [66] attempted to address these limitations 
by extensively screening human VH and VL scaffolds to 
isolate those with high stability, solubility, yield and suit-
ability for carrying CDR mutations. They then selected three 
of the most suitable scaffolds and carried out targeted trinu-
cleotide mutagenesis of CDRs producing libraries of ~ 1010 
diversity. High affinity ligands (low nM) were isolated but 
the general limitations of human single domain antibodies 
were not resolved. These issues may be due to human VH 
and VL domains usually being paired in nature resulting in 
the burying of hydrophobic surfaces that are surface exposed 
in the equivalent single domain structures.
Camelid  VHH Nanobodies
VHHs are derived from heavy chain antibodies (HCAbs) as 
first described in 1993 [67] and consist of the equivalent of a 
conventional IgG VH domain (Fig. 1). HCAbs are naturally 
found in camels, alpacas and llamas where they make up a 
significant proportion of the IgG population. For example, in 
alpacas IgGs occur in a ratio of approximately 5:3:2 for IgG1 
(conventional IgG structure):IgG2  (VHH with a short hinge 
length):IgG3  (VHH with a long hinge length), and so HCAbs 
can make up approximately 50% of circulating IgG [68].
Similarities between  VHH and the VH domain of a typical 
IgG are the presence of a disulphide bond between frame-
work regions (FRs) that stabilises the structure, as well 
as it being composed of 3 CDR regions held by scaffold 
FRs with beta-sheet structure. Differences between the VH 
domain and  VHH include the latter often having an addition 
disulphide bond between CDR1 and CDR3 that reduces the 
flexibility of the paratope, the CDRs 1 and 3 are generally 
longer in  VHH and its FR2 region is more hydrophilic. This 
latter property prevents the FR2 region interacting with a 
light chain and also results in higher solubility compared 
to the VH domain [69–71].  VHHs usually have relatively 
high stability and solubility and can very effectively refold 
after heat denaturation. Their high stability means they often 
have a high tolerance to organic solvents [72] and tempera-
ture making them very adaptable reagents in assays.  VHHs 
also have some unusual binding characteristics in that the 
reduced size of their paratope (made up of 3 rather than 6 
CDR regions) with an often extended CDR3 leads to effec-
tive binding within ‘pockets’ such as enzyme active sites. 
However,  VHH binders have been identified to a wide range 
of antigens including more ‘flat’ structures [20, 68]. It has 
been suggested that a relatively small paratope may be a dis-
advantage when binding haptens, and whilst in vivo camelid 
antibodies against such antigens tend to be dominated by 
IgG1, there are numerous examples where phage displayed 
 VHHs have been isolated to haptens [20], indicating they 
have a broad range of potential epitopes. When considering 
 VHHs as in vivo reagents, their small size may allow supe-
rior tissue/tumour penetration compared to larger antibody 
formats, their lack of an Fc region means they provoke less 
immune effector responses and they have a relatively rapid 
distribution and subsequent clearance. These traits indicate 
that they are good candidates as ligands for producing high 
contrast images [72]. Indeed, single domain antibodies have 
already been developed into various molecular imaging trac-
ers [73–77].  VHHs with potential therapeutic applications 
have also recently been described [78–80].
The isolation of  VHHs often involves the immunisation 
of camelids and the subsequent production of an immune 
phage display library. Obvious limitations of this approach 
are that each library is only valid for a single (or limited 
number) of antigens, the cost of keeping the animals is high 
and toxic antigens cannot be used. However, there are now 
in vitro alternatives to this approach. One strategy that has 
been recently demonstrated is to stimulate camelid B cells 
in vitro with antigen in the presence of IL2 and IL4 and then 
clone a small  VHH display library of ~ 106 repertoire [81]. 
Alternatively, single-pot  VHH phage display libraries have 
been produced and range in diversity from ~ 107 to ~ 109 [18, 
69, 82–85]. These can be produced from natural diversity 
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or by engineering diversity into the CDR regions of a scaf-
fold  VHH. For example, Sabir and co-workers amplified and 
cloned the natural diversity of  VHHs for both IgG2 and IgG3 
producing a library with  107 diversity [69]. For synthetic 
libraries, Yan et al. [18] used the cAbBCII10  VHH template 
as an effective scaffold for grafting in CDR diversity, this 
scaffold has high stability and expression levels and lacks 
the CDR1-CDR3 disulphide bond [86]. They introduced a 
16-amino acid random insert into the CDR3, using the NNK 
codon, to produce a  109 library. Cloning used an overlap-
ping PCR method to amplify the  VHH gene with the overlap 
in the FR3 domain. Interestingly,  VHHs isolated from this 
library against distinct targets had very different expression 
levels in bacteria indicating the significant contribution of 
the CDR3 region to antibody yields.
The expression levels of  VHHs is relatively high in both 
bacterial and eukaryotic expression systems and this is often 
accompanied by high thermal stability. For example, bacte-
rial expression often produces > 5 mg/L of  VHH [18, 71, 
86]. Studies have looked at further improving thermal stabil-
ity [87, 88] by the introduction of an extra disulphide bond 
between FR2 and FR3. This approach usually increased ther-
mal stability but often resulted in lower expression levels 
and in one case also reduced refolding after heat denatura-
tion [71]. An additional strategy was to then introduce nega-
tively charged amino acid substitutions into FRs to lower the 
isoelectric point of the  VHH. This was shown to improve 
expression and refolding properties for some antibodies 
[71], however, it did not increase yields for all  VHHs with 
the extra disulphide bond. Overall, this strategy presents 
an additional or alternative approach for the stabilisation 
of  VHHs.
In summary,  VHHs have greater stability than other anti-
body formats and are expressed at relatively high levels in 
bacteria. Their smaller size and smaller paratope does not 
seem to constrain the binding properties of  VHHs isolated 
in  vitro.  VHHs may also offer advantages when target-
ing ‘buried’ epitopes such as the active sites of enzymes. 
Compared to other antibody formats,  VHHs may also offer 
improved tumour penetration for in  vivo applications. 
Improving  VHH in vivo properties such as effector function 
and increased serum half-life may be achieved by fusion to 
an Fc domain. This has been achieved for individual  VHHs 
[89] and should be feasible for batch reformatting of  VHHs 
from phage display experiments in analogous procedures to 
those for scFv-Fc and scFab-Fc formats.
Shark  VNAR Nanobodies
There are relatively few examples of  VNAR phage display 
libraries compared to scFv, Fab and  VHH formats. The  VNAR 
structure is analogous to  VHH in that it has a relatively long 
CDR3 region of up to 40 amino acids, averaging ~ 18 resi-
dues [19, 90] and this region represent most of the diversity. 
They also have disulphide bonds that stabilise their structure 
(including a canonical bond between FR1 and FR3), and 
are relatively small at ~ 12 kDa. Similar to  VHHs,  VNARs are 
highly stable. However,  VNARs do not have a CDR2 region, 
instead they have 2 mutation-prone regions between CDR1 
and CDR3 termed HV2 and HV4 [19, 91]. The  VNARs are 
classified as Type 1 to Type 4 depending on the number and 
location of non-canonical disulphide bonds [18, 91]. Type 1 
contains 2 cysteine residues in CDR3 that form bonds with 
residues in FR1 and FR4, type 2 have a bond between CDR3 
and CDR1, type 3 are similar to type 2 but with a conserved 
tryptophan adjacent to the bond location in CDR1 and type 
4 have none of the non-canonical bonds that are seen in the 
other 3 types. Feng et al. also describe further types of  VNARs 
that are yet to be classified [19]. Type 1, 2 and unclassified 
 VNARs with specific binding properties have been isolated 
from phage display experiments [19, 90, 92–94].  VNARs are 
from a single gene family and so are very easily cloned, just 
3 primers in 2 PCR reactions have been used to clone  VNAR 
diversity [90]. Both immune and single-pot phage libraries 
have been produced. Immune libraries of ~ 106 to  107 diver-
sity have been reported [90, 94, 95], one of which yielded an 
antibody with low nM affinity [90]. Up until very recently, 
single-pot libraries were produced from a range of shark 
species but with relatively low diversities of ~ 107 [92, 93, 
95, 96]. These libraries were either synthetic [92, 97] based 
on up to 26 scaffold sequences and randomised CDR3, a 
mixture of synthetic CDR3 diversity and natural diversity 
[93] or had completely natural diversity [96]. A naïve library 
with high diversity has recently been produced by Feng et al. 
[19]. They used a method termed PCR extension assembly 
and self-ligation (EASeL) to produce a library with diversity 
of ~ 1 × 1010. The method amplified the  VNAR gene region 
and a phagemid vector separately, both with a complemen-
tary overhang. Both products were then amplified together 
in a subsequent extension PCR, followed by self-ligation. 
The library was used to isolate binders to diverse targets and 
one binder had an affinity of 10 nM. Across all studies, the 
 VNARs could be produced in E. coli but with varying levels 
of expression, between ~ 0.2 and 15 mg/L [19, 93]. Zadeh 
et al. has also produced a synthetic  VNAR library based on 
the anti-lysozyme HEL-5A7  VNAR clone, introducing diver-
sity into a 12 to 23 amino acid CDR3 [98].
As with  VHHs, batch reformatting of  VNARs into IgG-
like structures to improve in vivo properties has not been 
reported. However, individual  VNARs have been converted 
into  VNAR-Fc fusions [99]. Batch reformatting of this type 
of antibody should therefore be feasible using analogous 
procedures to those for scFv-Fc and scFab-Fc formats.
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Conclusions and Future Perspectives
This review has considered the phage display of Fabs, scFvs 
and nanobodies. With potential application to all recombinant 
antibody library types are the recent improvement in library 
design and display efficiency. The diversity within the CDR 
regions can now be designed with considerable accuracy by 
using trimer phosphoramidine codons to mimic natural amino 
acid usage [52]. Furthermore, improvements have been made 
in reducing cloning errors due to the presence of linker repeat 
regions [49]. Both advances will facilitate the optimal clon-
ing of diversity into libraries in the future. The co-expression 
of chaperones and isomerases [34, 36] as well as the use of 
the co-translation secretion pathway with optimised signal 
sequences [25] can significantly improve antibody phage dis-
play efficiency, thereby improving the efficiency of isolating 
binders. These same strategies also improve soluble antibody 
expression levels. Furthermore, the identification and use of 
highly stable Fabs and scFvs as scaffold for the introduction 
of synthetic diversity have improved expression and stability 
of the resulting antibody fragments [31, 32, 50, 66]. The com-
bined use of these strategies to yield higher expression levels 
and increased stability has the potential to produce more effi-
cient phage display of antibodies and therefore improve pan-
ning efficacy. They should also produce more useful reagents.
Methods suitable for the batch reformatting of both Fabs 
and scFvs into IgGs for high-level expression in mammalian 
cell culture are now also described [26, 27, 58, 59]. These 
will facilitate the efficient cloning of sub-libraries of anti-
body fragments from panning experiments to allow them to 
be screened as IgGs. This has previously been a bottleneck 
in developing therapeutics from phage display libraries, as 
the monovalent recombinant antibody fragments often have 
very different properties to their concomitant divalent IgGs.
Nanobodies from both camelids and sharks are readily 
amenable to the production of simple, high diversity phage 
display libraries [18, 19]. They provide small antibodies 
with very high stability, therefore potentially offering unique 
properties for diagnostic or even therapeutic applications. In 
addition, the production of renewable polyclonal scFv from 
phage display experiments has now been demonstrated and 
may also provide a new type of diagnostic reagent [63].
Overall, improved methods for the accurate cloning of 
libraries, more efficient display of antibodies on phage, 
improved expression levels for soluble antibodies and the 
ability to screen in multiple antibody formats has the poten-
tial to significantly improve the application of phage display 
to generate an ever-wider range of diagnostic and therapeutic 
antibodies.
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